Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 28;14:4551. doi: 10.1038/s41467-023-40272-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — Neutralizing antibody titers against the Ancestral (a), Gamma (b), Delta (c), Omicron BA.1 (d) and Omicron BA.5 (e) variants of SARS-CoV-2 in plasma samples of individuals boosted with the indicated vaccine (ARVAC CG 25 µg, ARVAC CG 50 µg or BNT162b2) prior booster administration (d1) or at the indicated days after booster administration (d14, d21, d28). Each point represents the nAb titer of a volunteer. Data are from participants with no missing data at all analyzed time points (ARVAC CG 25 µg (N = 58), ARVAC CG 50 µg (N = 18) or BNT162b2 (N = 18). The nAb GMTs and 95% CIs are shown as horizontal and error bars, respectively. The numbers depicted above the individual points for each specified time point and viral variant represent the GMTs. The number of participants included in each data set analyzed is depicted in the bottom of the graph (N = number of individuals in each data set). Statistical differences were analyzed using the Kruskal-Wallis test followed by the Dunn´s multiple comparison test. P-values are depicted above the data sets that were compared. ns: P > 0.05. Exact P-values for each comparison are: BNT162b2 d21 vs. ARVAC CG 25 µg d14: P = 0.000007 (b), P = 0.0472 (c), P = 0.00001 (d) and P = 0.049 (e); BNT162b2 d21 vs. ARVAC CG 25 µg d28: P = 0.0016 (b), P = 0.015 (c), P = 0.0003 (d) and P = 0.0002 (e); BNT162b2 d21 vs. ARVAC CG 50 µg d14: P = 0.0006 (b), P = 0.00003 (d) and P = 0.0110 (e); BNT162b2 d21 vs. ARVAC CG 50 µg d28: P = 0.0033 (d) and P = 0.0171 (e). f Fold increases in the GMT from day 1 to day 21 or 28 (GMFR) for each specified variant represented by a point and written with a number followed by a ×. The horizontal lines represent the 95% CIs. Data are from participants with no missing data at baseline and at all time points analyzed (ARVAC CG 25 µg (N = 58), ARVAC CG 50 µg (N = 18) or BNT162b2 (N = 18). Statistical differences were analyzed using Kruskal-Wallis test followed by the Dunn´s multiple comparison test. ns: P > 0.05, ^★P = 0.0243; ^★★★P = 0.0009; ^★★★★P = 0.00004.